Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
Q4 2011 Earnings Call
January 31, 2012 10:00 am ET
Charles E. Triano - Senior Vice President of Investor Relations
Ian C. Read - Chairman, Chief Executive Officer and Member of Executive Compliance Committee
Frank A. D'Amelio - Chief Financial Officer, Executive Vice President of Business Operations and Member of Executive Compliance Committee
Olivier Brandicourt - President of Worldwide Primary Care Business and General Manager of Worldwide Primary Care Business
David S. Simmons - President of Emerging Markets & Established Products units and General Manager of Emerging Markets & Established Products units
Geno J. Germano - President of Pfizer Specialty Care & Oncology and General Manager of Pfizer Specialty Care & Oncology
Mikael Dolsten - Senior Vice President and President of Pfizer Worldwide Research & Development
Catherine J. Arnold - Crédit Suisse AG, Research Division
Jami Rubin - Goldman Sachs Group Inc., Research Division
Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division
Gregory B. Gilbert - BofA Merrill Lynch, Research Division
John T. Boris - Citigroup Inc, Research Division
Marc Goodman - UBS Investment Bank, Research Division
Barbara A. Ryan - Deutsche Bank AG, Research Division
Steve Scala - Cowen and Company, LLC, Research Division
David Risinger - Morgan Stanley, Research Division
Christopher Schott - JP Morgan Chase & Co, Research Division
Jeffrey Holford - Jefferies & Company, Inc., Research Division
Charles Anthony Butler - Barclays Capital, Research Division
Seamus Fernandez - Leerink Swann LLC, Research Division
Previous Statements by PFE
» Pfizer's CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Pfizer's CEO Discusses Q2 2011 Results - Earnings Call Transcript
» Pfizer's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Charles E. Triano
Good morning, and thank you for joining us today to review Pfizer's fourth quarter 2011 performance. I'm joined today by our Chairman and CEO, Ian Read; Frank D'Amelio, our CFO; Olivier Brandicourt, President and General Manager of Primary Care; Mikael Dolsten, President of Worldwide Research and Development; Geno Germano, President and General Manager of Specialty Care and Oncology; Amy Schulman, General Counsel, President and General Manager of Pfizer Nutrition; and David Simmons, President and General Manager of Emerging Markets and Established Products.
The slides that will be presented on this call can be viewed on our homepage, pfizer.com, by clicking on the link Pfizer Quarterly Corporate Performance Fourth Quarter 2011 located in the Investor Presentation section in the lower right-hand corner of this page.
Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer's 2010 annual report on Form 10-K and in our reports on Forms 10-Q and 8-K. Also the discussions during this conference call will include certain financial measures that were not prepared in accordance with generally accepted accounting principles. Reconciliation of those non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in Pfizer's current report on Form 8-K dated today, January 31, 2012.
With that, I'll now turn the call over to Ian Read. Ian?
Ian C. Read
Thank you, Chuck, and good morning, everyone. During my remarks this morning, I will briefly recap some highlights from the fourth quarter and for the year, and I'll talk about what we are focusing on for 2012.
We finished 2011 with a solid fourth quarter and the overall financial performance for the year was strong.
Looking at the quarter, losses of exclusivity continued to impact our business. This quarter, we absorbed nearly $1.3 billion revenue decline due to losses of exclusivity across our Biopharmaceutical commercial units. We saw strong operational growth in key markets such as Japan and China. Revenues in the Emerging Market business overall declined 2% operationally due to pricing pressures and exceptional items that Frank will review in more detail.
As we have said before, the opportunity in Emerging Markets remains attractive, although quarter-to-quarter performance is volatile. I believe the best measure of our business in these markets is the yearly performance, which I will speak to in a moment.
Animal Health, Nutrition and Consumer all turned in strong quarters operationally. Animal Health grew 13%, Nutrition grew 20% and Consumer grew 8% over the same quarter in 2010. And we saw the benefits of our process improvements and cost reduction work this quarter. Adjusted total costs were down 5% operationally.
Turning now to highlights for the year. We met or exceeded every aspect of our financial guidance. We reduced our adjusted R&D spend by nearly $1 billion compared to 2010, but we also took significant actions to strengthen our innovative core, which included: narrowing our therapeutic areas of focus; sharpening our analytical tools to better prioritize investment and stop funding low-potential programs earlier in the R&D cycle; advancing the most promising compounds within our pipeline; and continuing to invest in R&D network and the capability design to drive biomedical innovation.
During the year, the Emerging Markets business was affected by strong headwinds such as: increased pricing pressure in China and Turkey, the loss of exclusivity of Lipitor in Brazil and Mexico in 2010 and devaluation of Venezuela. That being said, revenue in Emerging Markets grew 5% operationally in 2011, comprised of 10% volume growth and a 5% decline in price. Performance was particularly strong in key markets where we increased our investment, such as China, which delivered 18% operational revenue growth, and Turkey, which delivered 17% operational growth for 2011.
We grew revenues from key assets in our branded portfolio including Prevnar 13, Lyrica, Enbrel and Sutent. We absorbed approximately $5 billion in LOE and operationally, only saw a slight decline in our revenues year-over-year.